These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38953634)

  • 1. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2.
    Yu F; Liu X; Ou H; Li X; Liu R; Lv X; Xiao S; Hu M; Liang T; Chen T; Wei X; Zhang Z; Liu S; Liu H; Zhu Y; Liu G; Tu T; Li P; Zhang H; Pan T; Ma X
    mBio; 2024 Aug; 15(8):e0108824. PubMed ID: 38953634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HRH1 as an alternative receptor for SARS-CoV-2: insights from viral inhibition by repurposable antihistamines.
    Zhong G; Li J; Wang H
    mBio; 2024 Aug; 15(8):e0169724. PubMed ID: 39037273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
    Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
    Elife; 2020 Oct; 9():. PubMed ID: 33103998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    Muralidar S; Gopal G; Visaga Ambi S
    J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
    Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
    Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide S4 is an entry inhibitor of SARS-CoV-2 infection.
    Liang Z; Wang J; Zhang H; Gao L; Xu J; Li P; Yang J; Fu X; Duan H; Liu J; Liu T; Ma W; Wu K
    Virology; 2024 Sep; 597():110149. PubMed ID: 38917689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
    Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
    Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
    Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
    J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.